Molecular Docking Studies of α-Glucosidase Inhibitors

α-Glucosidase inhibitors serve as critical agents in the management of post-prandial hyperglycaemia by delaying carbohydrate digestion at the small-intestinal brush border. Molecular docking has emerged as a cornerstone computational technique for assessing how small-molecule ligands orient and bind within the active site of α-glucosidase, predicting both binding affinity and key interactions such as hydrogen bonding, hydrophobic contacts and π-stacking. Advances in protein structure determination have enabled high-resolution models of human and microbial α-glucosidases, facilitating virtual screening of diverse chemical libraries. Through iterative cycles of in silico docking and in vitro validation, researchers have identified novel scaffolds—including heterocyclic cores, natural products and hybrid derivatives—with nanomolar to micromolar inhibitory potency. Structural insights from docking have guided the optimisation of substituent patterns around critical residues such as Glu277, Asp349 and His351, improving both selectivity and pharmacokinetic profiles. This blend of computational and experimental strategies underpins the accelerated discovery of next-generation antidiabetic agents.

Research from Nature Portfolio

Recent studies have employed bis-Schiff base derivatives of thiobarbituric acid as a novel class of α-glucosidase inhibitors. Following multi-step synthesis and spectroscopic characterisation, these compounds exhibited sub-micromolar IC50 values, outperforming standard acarbose. Molecular docking pinpointed key interactions with the catalytic pocket, notably hydrogen bonds to acidic residues and stabilising hydrophobic contacts. Density functional theory calculations further elucidated intramolecular hydrogen bonding networks that enhance binding affinity. The combination of docking and quantum-chemical analysis has thus provided a blueprint for refining potency and guiding lead optimisation.

Molecular Docking Studies of α-Glucosidase Inhibitors publication trend

The graph below shows the total number of articles in molecular docking studies of α-glucosidase inhibitors across all publications each year (not limited to Nature Index journals).

Technical terms

α-Glucosidase: An enzyme that catalyses the hydrolysis of terminal, non-reducing 1,4-linked α-glucose residues in carbohydrates.

Molecular docking: A computational method for predicting the preferred orientation and binding affinity of a small molecule within a protein’s active site.

IC50: The concentration of an inhibitor required to reduce enzyme activity by 50%, a standard measure of potency.

Hydrogen bond: A non-covalent interaction between a hydrogen atom covalently bonded to an electronegative atom and another electronegative atom, crucial for ligand binding specificity.

References

1. Synthesis, Molecular Docking, and Bioactivity Study of Novel Hybrid Benzimidazole Urea Derivatives: A Promising α-Amylase and α-Glucosidase Inhibitor Candidate with Antioxidant Activity. Pharmaceutics (2023).
2. Honokiol as an α-glucosidase inhibitor. Frontiers in Pharmacology (2024).
3. The Synthesis, In Vitro Bio-Evaluation, and In Silico Molecular Docking Studies of Pyrazoline–Thiazole Hybrid Analogues as Promising Anti-α-Glucosidase and Anti-Urease Agents. Pharmaceuticals (2023).
4. Synthesis, molecular docking and DFT analysis of novel bis-Schiff base derivatives with thiobarbituric acid for α-glucosidase inhibition assessment. Scientific Reports (2024).